Immune Response to COVID-19 Vaccination in Frontline Healthcare Workers

Author:

Strukcinskiene Birute1ORCID,Valotkiene Zydre12,Jurgaitis Jonas1,Grigoliene Rasa3ORCID,Genowska Agnieszka4ORCID

Affiliation:

1. Faculty of Health Sciences, Klaipeda University, LT-92294 Klaipeda, Lithuania

2. Epidemiology Sub-Division, Infection Control Department, Vilnius University Hospital Santaros Klinikos, LT-08661 Vilnius, Lithuania

3. Faculty of Marine Technologies and Natural Sciences, Klaipeda University, LT-92294 Klaipeda, Lithuania

4. Department of Public Health, Medical University of Bialystok, 15-295 Bialystok, Poland

Abstract

This study evaluated the immune response to vaccination against COVID-19 in 534 healthcare frontline workers in Vilnius, Lithuania. The incidence of COVID-19 was reduced significantly after vaccination started in the healthcare sector. SARS-CoV-2 antibodies were detected in groups V–VII and this level of antibodies was found to be effective in preventing COVID-19. Sustained immune response was achieved after two vaccination doses, which remained stable for up to 6 months. After the booster dose, antibody levels remained high for an additional 12 months. Although SARS-CoV-2 antibody levels decreased after 6 months, even lower levels of antibodies provided protection against the Delta strain. The booster dose distributed the antibody titer in the high-level antibody groups, offering maximum protection at 12 months. However, even individuals with high antibody titers were observed to contract COVID-19 after vaccination with a booster dose and 6 months in the presence of the Omicron strain. Unfortunately, high levels of antibodies did not provide protection against the new strain of COVID-19 (the Omicron variant), posing a risk of infection. When comparing the antibody titer of vaccinated participants without COVID-19 and those with COVID-19, the change in antibodies after vaccination was significantly lower in infected participants. Individuals with comorbidities and specific conditions had lower antibody levels.

Funder

Medical University of Bialystok

Publisher

MDPI AG

Reference35 articles.

1. World Health Organization (2023, November 04). Vaccines and Immunization. Available online: https://www.who.int/health-topics/vaccines-and-immunization.

2. European Commission (2023, November 14). Questions and Answers on COVID-19 Vaccination in the EU. Available online: https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans/questions-and-answers-covid-19-vaccination-eu_en.

3. The COVID-19 pandemic impact on the Polish medical personnel work: A survey and in-depth interviews study;Wieczorkowska;Front. Public Health,2023

4. Asymptomatic SARS-CoV-2 infection among healthcare workers in a non-COVID-19 teaching university hospital;Mukhtar;J. Public Health Res.,2021

5. Seroprevalence study of SARS-CoV-2 antibodies in healthcare workers following the first wave of the COVID-19 pandemic in a tertiary-level hospital in the South of Ireland;Faller;BMJ Open,2021

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3